A NEW, OPIOID-FREE PAINKILLER
- Non-opioid painkiller – pre-clinical stage
- Lasts up to 300% longer than leading competitor*
- 22 U.S. Patents
InSitu Biologics is currently in the pre-clinical stage
WHO WE ARE
InSitu Biologics is an emerging biotech company focusing on development of AnestaGel™, a long-lasting and long-acting non-opiate painkiller. The sustained release drug AnestaGel is expected to be used in post-operative surgical procedures. AnestaGel may be a solution in relieving pain for broken bones, cosmetic surgery, hip/knee replacements, hernia, and more.
InSitu Biologics' lead product, AnestaGel™, is a long-lasting and long-acting non-opiate painkiller, targeted for use in peri-operative regional pain management.
- 22+ US Patents Issued, with matching OUS positions
- Hydrogel technology licensed from Cleveland Clinic Foundation
- Tunable, biocompatible, and pH neutral platform
- High dose drug-load reservoir capacity with a predictable pharmacological effect
- Non-opioid pain relief option
Filed additional patent(s)
White Paper published
Completed maximum dosing study with no toxicity
Presented at PODD-Boston
Completed first GLP study
Proved more pain relief compared to Exparel in pre-clinical study
GLP publication accepted
Raised over $400k
Completed Financial Audit
Converted all debt
Filed $10,000,000 RegA+ Offering
Launch RegA+ Offering
Announce GLP Paper by Hutchins & Taylor
Begin Phase 1 program manufacturing
Announce final GLP Study results
Expect approval for Phase 1 Clinical Study of AnestaGel
Jim has been the founder, inventor, investor, and owner operator in many med-tech ventures. Jim began working on the Matrix technology in 2007 and co-founded InSitu Biologics in 2014. Jim is an inventor on over 40 issued patents for medical products, and specializes in the total enterprise of bringing proprietary products from “just an idea” through design, scaled up manufacturing, and “to the patient”. Jim earned his Bachelor of Science from Carroll University in Waukesha, Wisconsin and his MBA from Cardinal Stritch University in Milwaukee.
Bill TaylorChief Scientist
Bill is a Co-Founder of InSitu Biologics, beginning his work on the Matrix in 2007. Bill is a successful medical product development programs manager and scientist, and has been awarded over $900k in government research grants, and authored industry papers in chemical remediation and demilitarization utilizing biological systems. Bill has his Bachelor of Science from the University of Minnesota with a double major in Chemical Engineering and Biology.
Daniel SippleDO Medical Advisor
Dr. Dan is a Co-Founder of InSitu Biologics, and a physiatrist that specializes in the diagnosis, treatment and rehabilitation of a variety of musculoskeletal and pain disorders, with an emphasis on spine care. Dan performs numerous interventions, including epidural steroid injections, radiofrequency, spinal cord stimulation and ultrasound guided procedures. A graduate of the University of Minnesota, Dan attended medical school at Des Moines University, doing his internship at the University of Massachusetts Medical Center and residency at the Rehabilitation Institute of Chicago. Dr. Sipple completed his fellowship training in interventional pain medicine through Sinai Hospital of Baltimore, MD. Dan is an inventor and co-inventor on multiple medical products.
Jacob HutchinsMD Medical Advisor
Jake was the Principal Investigator for the InSitu GLP Study comparing AnestaGel™ to Exparel, and Jake is the Director of the Regional Anesthesia Acute Pain and Ambulatory Surgery division at the University of Minnesota. Jake is also the medical director for the M Health Ambulatory Surgery Center. His current research interests include ultrasound-guided regional anesthesia in adult and pediatric acute postoperative pain as well as ambulatory anesthesia. His research also involves the use of liposomal bupivacaine for postoperative pain control in a variety of surgical procedures. Jake is a life-long Minnesota native and a graduate of the University of Minnesota Medical School, 2007.